抗厌氧菌药物临床应用进展(3)
[7]全晶晶，王瑶，季京淑，等.拉氧头孢肠杆菌科细菌及厌氧菌的体外抗菌活性观察[J].中华医学杂志，2016，96(18)：1459-1464.
[8]Theriot C M，Schumacher C A，Bassis C M，et al.Effects of tigecycline and vancomycin administration on established Clostr-idium difficile infection[J].Antimicrobial Agents& Chemotherapy，2015，59(3)：1596.
[9]Kanj S S，Whitelaw A，Dowzicky M J.In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011[J].International Journal of Antimicrobial Agents，2014，43(2)：170-178.
[10]张小盼，于秋影，王文静，等.亚胺培南西司他丁钠致老年患者血液系统毒性1例[J].中国医院用药评价与分析，2016，16(11)：1582-1583.
[11]George J M，Towne T G，Rodvold K A.Prolonged infusions of β-lactam antibiotics： implication for antimicrobial stewardship[J].Pharmacotherapy the Journal of Human Pharmacology& Drug Therapy，2012，32(8)：707-21.
[12]Anderson D L.Doripenem[J].Clinical Infectious Diseases，2006，42(6)：399.
[13]Pumbwe L，Glass D，Wexler H M.Efflux Pump Overexpression in Multiple-Antibiotic-Resistant Mutants of Bacteroides fragilis[J].Antimicrobial Agents&Chemotherapy，2006，50(9)：3150-3453.
[14]Owens，RC，Paul G.Ambrose PG.Antimicrobial safety：focus on fluoroquinolones [J].Clin Infect Dis，2005，41(2)：S144-S157.
[15]Segawa J，Kitano M，Kazuno K，et al.Studies on pyridonecarboxylic acids.1.Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1，3]thiazeto[3，2-a]quinoline-3- carboxylic acids[J].Journal of Medicinal Chemistry，1992，35(25)：4727-4738.
[16]Citron D M，Tyrrell K L，Merriam C V，et al.In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria[J].Antimicrobial Agents&Chemotherapy，2010，54(4)：1627-1632.
[17]Andes D，Craig W A.Pharmacodynamics of a New Cephalos-porin，PPI-0903(TAK-599)，Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models：Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target[J].Antimicrob Agents Chemother，2014，58(4)：1376.
[18]《抗菌藥物临床应用指导原则》修订工作组.抗菌药物临床应用指导原则：2015年版[M].北京：人民卫生出版社，2015.
[19]买金荣，罗惠玲，李煜.临床药师参与抗厌氧菌感染的临床实践分析[J].中国临床药学杂志，2014(5)：328-331.
[20]Brook I.Treatment of anaerobic infection[J].Expert review of anti-infective therapy，2007，5(6)：991., http://www.100md.com(李连瑞 刘婕 陈志勇)
[8]Theriot C M，Schumacher C A，Bassis C M，et al.Effects of tigecycline and vancomycin administration on established Clostr-idium difficile infection[J].Antimicrobial Agents& Chemotherapy，2015，59(3)：1596.
[9]Kanj S S，Whitelaw A，Dowzicky M J.In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011[J].International Journal of Antimicrobial Agents，2014，43(2)：170-178.
[10]张小盼，于秋影，王文静，等.亚胺培南西司他丁钠致老年患者血液系统毒性1例[J].中国医院用药评价与分析，2016，16(11)：1582-1583.
[11]George J M，Towne T G，Rodvold K A.Prolonged infusions of β-lactam antibiotics： implication for antimicrobial stewardship[J].Pharmacotherapy the Journal of Human Pharmacology& Drug Therapy，2012，32(8)：707-21.
[12]Anderson D L.Doripenem[J].Clinical Infectious Diseases，2006，42(6)：399.
[13]Pumbwe L，Glass D，Wexler H M.Efflux Pump Overexpression in Multiple-Antibiotic-Resistant Mutants of Bacteroides fragilis[J].Antimicrobial Agents&Chemotherapy，2006，50(9)：3150-3453.
[14]Owens，RC，Paul G.Ambrose PG.Antimicrobial safety：focus on fluoroquinolones [J].Clin Infect Dis，2005，41(2)：S144-S157.
[15]Segawa J，Kitano M，Kazuno K，et al.Studies on pyridonecarboxylic acids.1.Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1，3]thiazeto[3，2-a]quinoline-3- carboxylic acids[J].Journal of Medicinal Chemistry，1992，35(25)：4727-4738.
[16]Citron D M，Tyrrell K L，Merriam C V，et al.In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria[J].Antimicrobial Agents&Chemotherapy，2010，54(4)：1627-1632.
[17]Andes D，Craig W A.Pharmacodynamics of a New Cephalos-porin，PPI-0903(TAK-599)，Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models：Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target[J].Antimicrob Agents Chemother，2014，58(4)：1376.
[18]《抗菌藥物临床应用指导原则》修订工作组.抗菌药物临床应用指导原则：2015年版[M].北京：人民卫生出版社，2015.
[19]买金荣，罗惠玲，李煜.临床药师参与抗厌氧菌感染的临床实践分析[J].中国临床药学杂志，2014(5)：328-331.
[20]Brook I.Treatment of anaerobic infection[J].Expert review of anti-infective therapy，2007，5(6)：991., http://www.100md.com(李连瑞 刘婕 陈志勇)